Johnson Bankole A.'s Form 4 filing
Adial Pharmaceuticals, Inc. (ADIL) · filed Oct 6, 2021
- Accession no.
- 0001213900-21-051646
- Filed
- Oct 6, 2021
- Trade date
- Oct 4, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction and 1 derivative transaction. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Johnson Bankole A.CIK 0001718158 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 4, 2021 | Common Stock | SSaleDisposed | −200,000 | –F1 | – | 148,246 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 4, 2021 | Common Stock | JOtherDisposed | −150,000 | –F3 | – | 39,714 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
En Fideicomiso De Mi Vida 11/23/2010 (the "Trust") sold 200,000 shares of the issuer's common stock pursuant to a Stock Purchase Agreement dated as of October 1, 2021 (the "SPA"), for an aggregate purchase price of $200,000.
Referenced by the price of 1 transaction in Table I.
- F3
On October 4, 2021, Dr. Johnson sold warrants to purchase 150,000 shares of the issuer's common stock pursuant to the SPA, for an aggregate purchase price of $1,500. The warrants provide for an exercise price of $6.25 per share and expire five years after issuance.
Referenced by the price of 1 transaction in Table II.